Acadian Asset Management
AQST icon

Acadian Asset Management’s Aquestive Therapeutics AQST Stock Holding History

Acadian Asset Management’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-533,567
Closed -$2.27M – 1740
2024
Q1 		$2.27M Sell
533,567
-16,917
-3% -$56.3K 0.01% 628
2023
Q4 		$1.11M Hold
550,484
– – ﹤0.01% 830
2023
Q3 		$841K Buy
550,484
+388,017
+239% +$667K ﹤0.01% 893
2023
Q2 		$267K Buy
+162,467
New +$294K ﹤0.01% 1206
2019
Q4 		– Sell
-19,090
Closed -$61K – 1862
2019
Q3 		$61K Buy
+19,090
New +$71.5K ﹤0.01% 1576
2019
Q2 		– Sell
-9,425
Closed -$65K – 1772
2019
Q1 		$65K Buy
+9,425
New +$66K ﹤0.01% 1613

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $40.4B AUM 21.2% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Acadian Asset Management's AQST Position: Q2 2024 in Review

Acadian Asset Management sold out of Aquestive Therapeutics (AQST) in Q2 2024, closing a stake of 533,567 shares — an estimated $2.27M sold.

Acadian Asset Management first reported a position in AQST in Q1 2019 and held it in 6 quarters. The position peaked at $2.27M in Q1 2024. 97 funds tracked by Wall St. Rank hold AQST as of Q2 2024.

  • Acadian Asset Management reported no remaining Aquestive Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Acadian Asset Management sold 533,567 Aquestive Therapeutics shares in Q2 2024, an estimated $2.27M.
  • Acadian Asset Management first reported a position in Aquestive Therapeutics in Q1 2019 and held it in 6 quarters.
  • Acadian Asset Management's Aquestive Therapeutics position peaked at $2.27M in Q1 2024.
  • 97 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2024.

Based on Acadian Asset Management's 13F filing for Q2 2024, filed 6 Aug 2024.